Reduced dosing versus full dosing valganciclovir for prophylaxis of cytomegalovirus in high‐risk abdominal transplant recipients
Maura L. Kreiser,
Robert Dupuis,
Kristen R. Szempruch
et al.
Abstract:BackgroundCytomegalovirus (CMV) is a common infection in abdominal transplant recipients (ATR). Prevention of CMV in the highest risk population (CMV IgG donor+/recipient‐) is critical as CMV is associated with negative outcomes. Guideline recommended prophylactic valganciclovir dosing is 900 mg daily for 6 months in this population. However, reduced dosing strategies are utilized in practice.MethodsThis single center, retrospective study in adult ATR compared full valganciclovir prophylactic dosing (900 mg da… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.